Lonza signs manufacturing deal with Immune Pharmaceuticals

Lonza signs manufacturing deal with Immune Pharmaceuticals

4:30 PM, 19th July 2011
Lonza signs manufacturing deal with Immune Pharmaceuticals
Dr Stephan Kutzer, COO, Custom Manufacturing, Lonza.

  • Contract covers the clinical phase 2 production of Bertilimumab (iCo-008), a human immunoglobulin monoclonal antibody under investigation for the treatment of several inflammatory disorders.
  • Lonza will manufacture Bertilimumab at its mammalian development facility.

BASEL, SWITZERLAND: Lonza announced an exclusive contract for the production of Immune Pharmaceutical’s human immunoglobulin monoclonal antibody, Bertilimumab, under investigation for the potential treatment of several inflammatory disorders. As per the agreement, Lonza will produce phase 2 clinical trial material at its mammalian development and manufacturing facility.

“We are excited about this opportunity to support Immune Pharmaceutical’s growing pipeline, This partnership is a direct reflection of our commitment to emerging pharmaceutical companies as they advance through clinical phase milestones,”

said Dr Stephan Kutzer, COO, Custom Manufacturing, Lonza.

“Lonza understands the needs of emerging companies, providing assistance and flexibility, while maintaining the highest standards essential for regulatory compliance and successful partnering,” said Dr Daniel Teper, CEO, Immune.

Additionally, Immune strengthened its internal bio-manufacturing expertise by appointing to its Board of Directors, Dr David Naveh, formerly the Chief Technical Officer of Bayer Biologics Worldwide.

© WOC News




Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Hydrogen may be key to growth of high-quality graphene

  OAK RIDGE, US: A new approach to growing graphene greatly reduces problems that have plagued researchers in the past and clears a path to the ...

Read more
Click chemistry with copper – A biocompatible version

BERKELEY, US: Biomolecular imaging can reveal a great deal of information about the inner workings of cells and one of the most attractive targets for ...

Read more
Topsoe Fuel Cell expands stack production

LYNGBY, DENMARK: Topsoe Fuel Cell is expanding its stack production facilities with kick-off in July 2011. The need for extra production capacity aris ...

Read more
Shell to exit Mackenzie gas pipeline project in Canada

CHINA TOWN, SINGAPORE: Shell will sell its stake in the $17 billion Mackenzie Gas Project, a Canadian pipeline project, the latest sign that the proje ...

Read more
Kerry Group in talks to acquire Cargill’s global flavours business

TRALEE, IRELAND: Kerry Group is in talks with Cargill which may or may not result in the group’s acquisition of Cargill’s global flavours ...

Read more
Albemarle appoints new CEO, Luke Kissam

BATON ROUGE, US: Albemarle Corporation has promoted Luther C Kissam to the position of Chief Executive Officer, effective September 1, 2011. Kissam jo ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X